XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Expenses:        
Research and development $ 3,380 $ 4,125 $ 9,898 $ 13,530
In-process research and development 30,393 0 30,393 0
General and administrative 3,947 2,843 10,770 8,671
Total operating expenses 37,720 6,968 51,061 22,201
Operating loss (37,720) (6,968) (51,061) (22,201)
Other income (expense):        
Investment income, net 337 41 496 111
Other expense, net 0 0 (149) (90)
Total other income (expense) 337 41 347 21
Net loss before benefit from income taxes and noncontrolling interests (37,383) (6,927) (50,714) (22,180)
Benefit from income taxes 0 0 (2,479) (1,508)
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (37,383) $ (6,927) $ (48,235) $ (20,672)
Basic and diluted loss per share        
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share) $ (7.88) $ (1.74) $ (11.28) $ (5.76)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share) $ (7.88) $ (1.74) $ (11.28) $ (5.76)
Weighted average common shares outstanding        
Basic shares 4,747 3,974 4,276 3,587
Diluted shares 4,747 3,974 4,276 3,587